American Association for Cancer Research 1998: promises and prospects for the next century

Bibliography

• END D, SKRZAT S, DEVINE A et al.: R115777, a novel imi- dazole farnesyl protein transferase inhibitor (FTD: biochemical and cellular effects in H-ras and K-ras dominant systems. Proc. Am. Assoc. Cancer Res. (1998) 39:270. Abstract 1847.
   Google Scholar
• ZUJEWSKI J, HORAK ID, WOESTENBORGHS R et al.: Phase I trial of farnesyl-transferase inhibitor, R115777, in advanced cancer. Proc. Am. Assoc. Cancer Res. (1998) 39:270. Abstract 1848.
   Google Scholar
• TODD AV, APPLEGATE TL, FUERY CJ et al.: Farnesyl transferase inhibitor (FTD: effect of ras activation. Proc. Am. Assoc. Cancer Res. (1998) 39:317. Abstract 2168.
   Google Scholar
• SKRZAT S, ANGIBAUD P, VENET M et al.: R115777, anovel imidazole farnesyl transferase inhibitor (FTO with potent oral antitumor activity. Proc. Am. Assoc. Cancer Res. (1998) 39:317 Abstract 2169.
   Google Scholar
• SMETS G, XHONNEUX F, CORNELISSEN D et al.: R115777,a selective farnesyl protein transferase inhibitor (FTD, induces anti-angiogenic, apoptotic and anti-proliferative activity in CAPAN-2 and in LoVo tumor xenografts. Proc. Am. Assoc. Cancer Res. (1998) 39:318. Abstract 2170.
   Google Scholar
• VENET M, ANGIBAUD P, SANZ G et al.: Synthesis and invitro structure-activity relationships of imidazoly1-2-quinolinones as farnesyl protein transferase inhibi-tors (FTD. Proc. Am. Assoc. Cancer Res. (1998) 39:318. Ab-stract 2171.
   Google Scholar
• LIU M, LEE S, YAREMKO B et al.: SCH 66336, an orallybioavailable tricyclic farnesyl protein transferase in-hibitor, demonstrates broad and potent in vivo antitu-mor activity. Proc. Am. Assoc. Cancer Res. (1998) 39:270. Abstract 1843.
   Google Scholar
• STRICKLAND C: Structural studies of farnesyl proteintransferase. Proc. Am. Assoc. Cancer Res. (1998) 39:270. Abstract 1844.
   Google Scholar
• KIRSCHMEIER P, CARR D, GRAY K et al: SCH 66336, an orally bioavailable tricyclic farnesyl transferase in-hibitor blocks anchorage-independent growth of Ras-transformed fibroblasts and human tumor cell lines. Proc. Am. Assoc. Cancer Res. (1998) 39:318. Abstract 2175.
   Google Scholar
• NJOROGE FG, TAVERAS A, KELLY J et al.: Orally active, trihalobenzo-cycloheptapyridine farnesyl protein transferase inhibitor antitumor agents. Proc. Am. Assoc. Cancer Res. (1998) 39:318. Abstract 2176.
   Google Scholar
• BRYANT MS, LIU M, WANG S et al.: Pharmacokinetics ofa potent orally bioavailable inhibitor of farnesyl trans-ferase in the mouse, rat and cynomolgus monkey. Proc. Am. Assoc. Cancer Res. (1998) 39:319. Abstract 2177.
   Google Scholar
• PRZYBRANOWSKI SA, VINCENT PW, LATHIA C et al In vivo evaluation of farnesyltransferase inhibitor, PD 169451 versus a panel of human tumor xenografts. Proc. Am. Assoc. Cancer Res. (1998) 39:269. Abstract 1841.
   Google Scholar
• LAVELLE F: American Association for Cancer Research: Progress and New Hope in the Fight Against Cancer. Exp. Opin. Inves. Drugs (1997) 6:771–775.
   PubMedGoogle Scholar
• DENNY WA, SMAILL JB, FRY DW et al: Structure-activity relationships for 4-anilinoquinazoline and related pyridopyrimidine acrylamides as specific, irreversi-ble inhibitors of the ATP site of the epidermal growth factor receptor. Proc. Am. Assoc. Cancer Res. (1998) 39:559. Abstract 3804.
   Google Scholar
• PATMORE SJ, ROBERTS BJ, STONER CL et al.: In vivo evaluation of the irreversible EGF receptor tyrosine ki-nase inhibitor PD 168393. Proc. Am. Assoc. Cancer Res. (1998) 39:560. Abstract 3805.
   Google Scholar
• FRY DW, NELSON JM, SLINTAK V et al.: Specific, irre-versible inhibitors of the epidermal growth factor re-ceptor (EGFID family of tyrosine kinases. Proc. Am. Assoc. Cancer Res. (1998) 39:560. Abstract 3806.
   Google Scholar
• VINCENT PW, AKINSON BE, ZHOU H et al: Characteriza-tion of the in vivo activity of a novel EGF receptor fam-ily kinase inhibitor, PD 169414. Proc. Am. Assoc. Cancer Res. (1998) 39:560. Abstract 3807.
   Google Scholar
• MEYER T, ZIMMERMANN J, GEIGER T et al: CGP 60474, aprotein kinase inhibitor with potent antitumor activ-ity in vivo at well tolerated doses. Proc. Am. Assoc. Can-cer Res. (1998) 39:558. Abstract 3794.
   Google Scholar
• RUETZ ST, WOODS-COOK K, SOLF R et al.: Effect of CGP60474 on cyclin dependent kinases (cdks), cell cycle progression and onset of apoptosis in normal and transformed cells. Proc. Am. Assoc. Cancer Res. (1998) 39:558. Abstract 3796.
   Google Scholar
• HANG H, DEY C, CHANG A et al: The importance of gly-cosylation and kringle 4 on the activity of human An-giostatinTM protein. Proc. Am. Assoc. Cancer Res. (1998) 39:46. Abstract 311.
   Google Scholar
• MACDONALD N, CHANG A, ZHOU XH et al: In vitro andin vivo characterization of CHO expressed human An-giostatinTM kringles 1–3 and kringles 1–4 proteins. Proc. Am. Assoc. Cancer Res. (1998) 39:46. Abstract 314.
   Google Scholar
• DIMITROFF CJ, KLOHS W, SHARMA A et al: Evaluation ofthe effects of PD166285 and PD173074 on in vitro and in vivo angiogenesis. Proc. Am. Assoc. Cancer Res. (1998) 39:96. Abstract 653.
   Google Scholar
• DRISCOLL D, STEINKAMPF R, HAMBY J et al.: Evaluationof tyrosine kinase inhibitors in in vitro models and angiogenesis. Proc. Am. Assoc. Cancer Res. (1998) 39:96. Abstract 654.
   Google Scholar
• WOOD J, BUCHDUNGER E, COZENS R et al.: Pharma-cological profile of a potent and orally active inhibitor of VEGF receptor tyrosine kinases. Proc. Am. Assoc. Cancer Res. (1998) 39:96. Abstract 655.
   Google Scholar
• TANAKA T, KONNO H, KAMIYA K et al: Prevention of he-patic metastases after primary resection by angiogene-sis inhibitor, irsogladine. Proc. Am. Assoc. Cancer Res. (1998) 39:98. Abstract 663.
   Google Scholar
• VAJKOCZY P, MENGER MD, VOLLMAR B et al.: Effect of the Flk-1 antagonist SU 5416 on tumor growth, angio-genesis and micro-hemodynamics. Proc. Am. Assoc. Cancer Res. (1998) 39:96. Abstract 651.
   Google Scholar
• FONG TAT, SHAWVER LK, APP H et al: SU 5416: a potent and selective Flk-1/KDR kinase inhibitor that blocks Flk-1 phosphorylation, endothelial cell mitogenesis, and tumor growth. Proc. Am. Assoc. Cancer Res. (1998) 39:560. Abstract 3811.
   Google Scholar
• FEDOROV OY, SALAZAR M, KERWIN SM et al: High-field NMR studies of G-quadruplex binding by a telomerase-inhibiting compound. Proc. Am. Assoc. Can-cer Res. (1998) 39:305. Abstract 2084.
   Google Scholar
• NAASANI I, SEIMIYA H, YAMORI T et al.: Screening for antitelomerase agents with the aid of COMPARE analy-sis. Proc. Am. Assoc. Cancer Res. (1998) 39:567. Abstract 3854.
   Google Scholar
• HASMANN M, LOSER R, BIEDERMANN E et al.: Effect of anovel class of antitumor compounds of multidrug re-sistant tumor cells. Proc. Am. Assoc. Cancer Res. (1998) 39:226. Abstract 1541.
   Google Scholar
• HASMANN M, LOSER R, SCHEMAINDA I et al.: Inductionof apoptosis by a novel class of non-DNA-damaging an-titumor compounds. Proc. Am. Assoc. Cancer Res. (1998) 39:226. Abstract 1542.
   Google Scholar
• MOOBERRY SL, TIEN G, PLUBRUKARN A et al: Discoveryof new microtubule stabilizing agents from a marine sponge. Proc. Am. Assoc. Cancer Res. (1998) 39:166. Ab-stract 1135.
   Google Scholar
• LONG BH, WASSERMAN AJ, CARBONI JM et al: Tubulinpolymerization induced by eleutherobin, a novel and potent cytotoxic agent. Proc. Am. Assoc. Cancer Res. (1998) 39:165. Abstract 1128. Francois Lavelle
   Google Scholar